Telix QSAM Inc (QSAM)

[Wrangler1]

Looks like they have an interim CFO. Hopefully they are making progress with their human trials.

[RandyKCMO]

I was mistaken.

I just noticed Chris Nelson is listed as Company Attorney.

Maybe someone else had overtaken the role of CFO.

[bobbyknobb]

Well IF that anchor/conman/ proven swindler / is cut away like the cancer he is. Better for longs here. But look to the issues of structure here. It's a set up and venture capital folks will be wiped out in reality.

[RandyKCMO]

I’m pretty sure there was an 8-K in the last month or two stating that the company has a new CFO… and that Nelson is no longer with the company. I’ll see if I can find it.

[Wrangler1]

Randy, isn’t Nelson still with QSAM? You mentioned that he is no longer with the company? We’re you speaking of QSAM or another company?

[RandyKCMO]

I’ve been watching and even advocating for this company for a while.

Your criticism of the company is only partly accurate… I understand that you and Chuck and other investors lost money with Chris Nelson and Kevin Bolin at the helm. Did they intentionally try to make the company fail? I doubt it.

What you don’t seem to have noticed is that both Bolin and Nelson are no longer with the company. Bolin was never a part of the reorganized company and Chris Nelson stayed on for just a year or so after the company was acquired by new management.

QSAM is a completely different entity than it has been before. Have you checked out their web page?

https://qsambio.com/#about

Check out the projects and potential they have:
https://ir.qsambio.com/

Have you read the bios of the folks involved?

https://ir.qsambio.com/company-information/management-team

These guys have successfully done this before. Have they reversed the previous shareholders to minimal levels? Sure. Did that affect me? Obviously. But that has undoubtedly affected Bolin and Nelson as well. You’ll probably enjoy knowing that at least a little.

My perspective might be simplistic, but the future success of the company is another matter. As an entity it is now making decisions that will hopefully allow those involved to bring a new drug to market AND hopefully provide a sizable return to those who have funded the venture…. the venture capitalists.

Proof of this, management‘s recent decision to walk away from a poorly structured VC offer. They didn’t like the terms even though it would have allowed them to uplist to NASDAQ. From what I can gather, they expect good outcomes from their drug trials and they will then be in a stronger negotiating position.

At this point, the only way for the investing public to participate in QSAM’s potential future success is to purchase shares in the open market… or possibly participate in some future share offering of it becomes available to the public.

[bobbyknobb]

I hear crickets and crashing. mmmmmmmmm

[bobbyknobb]

Hello. Anybody watching this pump and dump? Currently crashed down another 23% on 4 times avg. vol. Will It get pumped back on air? Or punish anyone who sells on down lower? All scammy.

[bobbyknobb]

Still fresh today. see dates of Chucks accurate post.

[bobbyknobb]

IMAC is a winner in this space. qsam is a swindal pump and dump keeping commons trapped.

[bobbyknobb]

GREETINGS!! well kids currently crashed down 15%. Yesterday was worse. After 40 for 1 second reverse split by chris nelson and qsam. Well this is EXACTLY HOW A PUMP AND DUMP WORKS!! regards. glta. PEACE

[bobbyknobb]

HOWDY !!! CURRENTLY CRASHED DOWN ONLY 29%. after the 1 for a million rev. split. slight exag. lol pump and dump. investors stay trapped=bagholder.

[bobbyknobb]

Hey Chuck...good post. so currently this pump and dump is down by 1/3 total value.....after that 2nd 1for40 rev. split. wow scam is good for insiders. glty

[ChuckFinley305]

Hey Bobby don't forget, this is the second reverse split since Nelson took control of the shell. The first was 7 to 1...

So actual current price is $0.023 for those who fell into this at the start.

-Chuck

[bobbyknobb]

ok OK 1 share given....40 taken RS. You were warned by me and Chuck. Now down 10%. This will never profit anyone but insiders. It's a stock selling scam. Just like chris nelson on cypw now defunct and gone $70 million taken. $0 given. SSDD

[Televet]

QSAM Biosciences, Inc. – Follow-On Offering



Issuer:

QSAM Biosciences, Inc.

Listing:

Current Listing: OTCQB: QSAMD

Listing on Nasdaq under the ticker symbol: QSAM

Expected Offering Size:

Approximately $20,000,000

Over-Allotment Option:

15% (100% Primary)

Expected Timing

March 24th

Sole Book-Runner:

ThinkEquity

Business Summary:

QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. The Company’s initial technology is Samarium-153 DOTMP, a/k/a CycloSam® (“CycloSam®” or the “New Technology”), a clinical-stage bone targeting radiopharmaceutical. CycloSam® features a patented, low specific activity form of Samarium-153, a beta-emitting radioisotope with a short 46-hour half-life, and the chelating agent DOTMP, which selectively targets sites of high bone mineral turnover and reduces off-site migration of the tumor-killing radiation.







Link to Preliminary Prospectus Supplement, filed with the SEC on March 10, 2022: https://www.sec.gov/ix?doc=/Archives/edgar/data/1310527/000149315222006465/forms-1a.htm

[Televet]

https://www.otcmarkets.com/filing/conv_pdf?id=15647553&guid=moFwkKDQe9wOB3h

[Renee]

QSAM one for 40 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[Fai 2]

Nice

[Wrangler1]

$QSAM Very big step today. Priority Review Vouchers, if obtained, are typically with north of $100M. Current market cap is $13M. Way undervalued here.

[Wrangler1]

https://finance.yahoo.com/news/qsam-biosciences-receives-rare-pediatric-133000623.html

[RandyKCMO]

I understand your negative bias. Losing money leaves a bread taste in your mouth. Fool me once shame on you; fool me twice shame on me. Maybe I’m naive, but in this case, the facts seem overwhelming.

My bias is in favor of the story and potential that’s pretty plain to see. This is no longer Chris Nelson’s show. His interest is largely from debt conversion and amounts to 4.9%. Other management and insiders own just over 53.5% of the company.

It seems to me he’s made connections with some pretty successful people and provided himself and other investors with a remarkable opportunity.

What do we know?

1. Management has a track record of success. Check out co-founders Douglas Baum and C.Richard Piazza’s bios. Then look up Link, Sugarman, Frank, and Simon. What’s not to love?

Just check out their website. https://qsambio.com/

Then compare the management/ insider ownership here: https://www.otcmarkets.com/filing/html?id=15429489&guid=OhvwkaoGobwyOth

2. Venture capitalists have been willing to commit substantial resources to the future success of the company. I've not added up the totals but I think it's between $3 and 5$ Million.

3. We have an actual drug with a proven history of effective treatment of bone cancer.

4. We have a drug in Phase 1 FDA Trial… that is really an improved drug with fewer side effects.

5. The value of the company surpasses the current drug candidate. QSAM has an exclusive license agreement on any future drugs or treatment protocols developed by IGL Pharma, Inc, the maker or developer of Samarium-153 DOTMP, known as CycliSam.

Will all this end with success or failure? Time will tell.

[ChuckFinley305]

A reverse split of 20:1 would be required to get the price to a level where up listing would be possible.

Its another pipe dream that has been sold on every stock ticker Chris Nelson has been associated with over the past 20 years. The reality is that the share price will continue its downward trend and up listing will never materialize.

-Chuck

[RandyKCMO]

I believe they stated that the reverse would only take place if it was in conjunction with uplisting to the NASDAQ Capital Market or for a listing the NYSE.

Maybe it goes down because of such uplisting... but generally, this is regarded as a positive step.

Cheers.

[ChuckFinley305]

Reverse split to get the share price higher, then authorize more shares to dilute... SOP of Chris Nelson.

$0.001 coming soon

-Chuck

[Televet]

Hi Randy,

Sheesh. This along with SPYR. Thanks for the news, I guess.

[RandyKCMO]

Management Authorized to do reverse split in conjunction with qualifying for NASDAQ Capitol Market or NYSE Listing

https://www.otcmarkets.com/filing/html?id=15467011&guid=faSwkpl1u7CdB3h

[ChuckFinley305]

Down on a 100,000+ share trades.. back up on a 5,000 trade.

Sure sign of dumping.. this is the toxic debt shares being sold for whatever price they can get for them. This will continue on and on until its sub penny.

It is the Chris Nelson way...

-Chuck

[bobbyknobb]

MARKETS AT RECORD HIGHS. this just lost 1/3rd. 32% crash. But hey reminder cypw chris got that scam on the QB board also. QB stands for qualifying board. It's just 1 step in proving this is even a real company. And last look up what it takes to qualify to the Nasdaq. This is many levels away from such lofty speak. But cons like Chris Nelson is an expert con atty. a penny stock pinks wizard.
Bragging and conning. Remember he was " gonna bring back to USA the LSR record. He took Millions. Car never moved on it's own. Not 1 foot. Investors lost $70 MILLION. composting was his true calling. all BS 24/7 365. PERIOD

[RandyKCMO]

Thanks for posting… I hadn’t seen this. I’ve been a QSAM fan since the reorganization.

[Newdie999]

I have family long in this one.. GLTA

[Newdie999]

4:57 pm ET *DJ QSAM Biosciences, Now on OTCQB Venture Market, Files for Stock Offering and Seeks Listing on Nasdaq Capital Market(Dow Jones)

[Newdie999]

News on TOS Platform after the bell...

[RandyKCMO]

Guess that means we are officially have a dog in Phase 1 of its development!!

[Televet]

QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer

https://finance.yahoo.com/news/qsam-biosciences-activates-clinical-sites-140000294.html

"The initiation of our first Phase 1 clinical trial of CycloSam is an important development for QSAM as it demonstrates the potential for treating bone cancers using our new approach. We look forward to driving enrollment forward and establishing a safety profile and understanding of CycloSam’s potential for efficacy,” stated Douglas R. Baum, QSAM’s CEO.

[ChuckFinley305]

Looks like they just sold off $555,000 of debit... with another $445,000 remaining..

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities x Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

13. Offering and Sales Amounts
Total Offering Amount $ 1000000 USD o Indefinite
Total Amount Sold $ 555000 USD
Total Remaining to be Sold $ 445000 USD o Indefinite

The capital funding acquired is tied to the stock, those "investors" aren't doing it because they believe in the company or the drug being developed. They are loaning the company money at interest that is backed by shares...

-Chuck

[ChuckFinley305]

There is a difference between not being successful at a venture and setting a venture up to not be successful from the start.

QSAM is the latest front for this scheme after CYPW failed, Q2P failed, Q2E failed... Failed is just an opinion because in reality in each of those instances Chris Nelson lined his pockets with cash. It was only the small investors that failed!

-Chuck

[ChuckFinley305]

Must have been the other mod then. Only 3 of us have the ability to edit that information.

Chris Nelson as CFO?? But he is "General" Nelson! He is a lawyer by education, he is not doing the accounting.

He is in charge of raising capital, he is one of the owners of the stock shell.... He is the real owner and the man behind the curtain.

What you should be asking is who is:

Last Name First Name Middle Name
Mayersohn Joel
Street Address 1 Street Address 2
420 ROYAL PALM WAY #100
City State/Province/Country ZIP/Postal Code
PALM BEACH FLORIDA 33480
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)

-Chuck

[RandyKCMO]

Your theory is pretty clear. Chris Nelson is a scam artist that is only interested in making money from unwary investors.

I don't believe that is the case. Has he been unsuccessful in the past? Yes... but such is the case. I've posted before that those who have taken ventures and pursued success are more likely to continue trying until they succeed.

I believe QSAM is the latest phase in this attempt for success.

I would assume at some point the information will be clear who owns what percent of the Company. I will be surprised if Mr. Melson owns more than 10-15% of the new company. We will have to wait to see.

[RandyKCMO]

So yes... the previous company has been rescued... but it has continued pursuing a business venture that seems to have a reasonable possibility of success.

According to your thinking... maybe they should have just put up the white flag and given up. And yet, how would have that helped... what good could come from ceasing to exist?

The direction they've gone has garnered significant investment from those closest to the company. Prior debt holders have received equity interest. I believe at this point the company is debt-free, but I'm not certain.

On top of this, I think the company has received venture Capital Funding in the millions of dollars, which means that those whose who know more than me... and possibly more than you are putting their money where their mouth is... have voted with their dollars on the future success of QSAM.

Plus if you look at the leadership page... the man who invented "Quadramet" is on the company's advisory board. I don't doubt that he knows very well the functional success anticipated on our first orphan drug candidate... "Cyclosam."

[RandyKCMO]

I have no idea what you're talking about. I'm not sure how I could remove anyone from the board.

All I did was cut and paste the information available on the https://qsambio.com/#about website...

and the management page that listed the company officers.

https://qsambio.com/#leadership



Chairman of the Board of Directors: C. Richard Piazza

Chief Executive Officer: Douglas R. Baum

Chief Medical Director: Dr. Charles G. Link

Senior Executive Generalist: Barry Sugarman

What role does the "villain" Chris Nelson have? He is the CFO... the Chief Finanical Officer. HE does the accounting... and reporting of the business that has taken place.

And what has become of the other person from the past... Kevin Bolen? Well he's gone. He took some equity interest and is no longer with the company.

[ChuckFinley305]

I see you removed the Chris Nelson information from the board... why? Don't want people to know who is really behind this?

You can make any story seem positive if you only show the positive aspects. To know the truth, you need the entire story.. good/bad/ugly...

-Chuck

[ChuckFinley305]

Randy,

Cyclone also had what seemed like a very strong leadership team, but in reality these people were not involved with the business at all with the exception of receiving stock as a form of payment for using their name.

Robert Edwards is a retired senior engineer from Lockheed Martin. Mr. Edwards served at Lockheed Martin for over 30 years, working on different projects including the Apollo Moon Project and other space programs. His area of expertise is in energy conversion systems, including thermoelectric, steam, internal combustion and external combustion engines. Mr. Edwards has also spent over 20 years working with experimental steam cars and other steam systems, and is an officer of the Mobile Steam Society in Tennessee. He has published over 40 scientific papers and now gives talks on the subjects of alternative fuels and heat transfer systems. He holds a B.S. from the University of Tennessee

George Nutz is technology consultant with almost 50 years experience working with external combustion and steam engines. He is the founder of Millennium Engineering Systems and Millennium Energy Systems, through which he has provided engineering guidance and expertise to multiple external combustion engine projects over the last twenty years.
Prior to consulting, Mr. Nutz was a staff research engineer at MIT Instrumentation Laboratory, part of the Department of Aeronautics and Astronautics. While in residence, he designed hardware and control systems, as well as steam cycles and applications. He represented MIT-IL at the Department of Transportation Clean Air / External Combustion hearings, and wrote several proposal papers outlining a working steam system. During this time he also became involved with steam automobile and steamboat groups and worked on boiler and engine designs/modifications, including being part of the MIT team designing and building a steam powered automobile for Saab for the MIT-Caltech “Clean Air Car Race”. Prior to his time at MIT, Mr. Nutz spent nine years at Bendix Aerospace designing gyro and guidance equipment and test platforms, and working with optics and sensors. He served in the U.S. Air Force and received his mechanical engineering degree from the New Jersey Institute of Technology in 1959.

Kevin P. Bowen retired from Raytheon Corporation as Chief Engineer for Maritime Vehicle Technology Development and has performed Systems Engineering development on manned and unmanned Surface and Undersea Vehicles for 30 years. He has held lead technical and management positions in the development of Riverine Combat Craft C4ISR, Autonomous Unmanned Surface Vehicles, Diver Detection Interdiction Systems, External Combustion Engines, Renewable Energy Systems, Large Scale Vehicle, MK 30 ASW Training Target System, proprietary UUV’s and Submarine Payloads & Sensors. He has been a major contributor to the US Navy and Japanese Deep Submergence Rescue Vehicles design, operation, test and evaluation. Kevin is Program Manager for Unmanned Surface Vehicle Technology Development and Diver Detection/ Intervention for Port Security. He is also Chief Engineer for UUV Propulsion Systems and Riverine Craft Combat System Architectures. Kevin was Technical Lead for Unmanned Underwater Vehicles (UUV’s) and Lead Systems Engineer on the MK 30 ASW Training Target System. Kevin was Technical Director for a proprietary UUV program at Applied Remote Technology. Mr. Bowen was responsible for design, production and test phases of the project. He directed the requirements development, alternatives selection, design definition, and validation for the project. Kevin was a Systems Engineering SME for the General Dynamics Electric Boat Advanced Seal Delivery System proposal. Mr. Bowen developed Japanese DSRV program sonar equipment specifications, installation, test, modification and acceptance procedures and taught a Japanese language course in theory and operation of sonar systems. Mr. Bowen worked on DSRV Mystic and Avalon navigation, ship control, sonar, television, communications, and side looking sonar systems. He was a Field Engineer responsible for Ship’s Inertial Navigation Systems on board the USNS Bowditch Oceanographic Survey Ship.

Peter Platell currently serves as CEO of his Company Ranotor Utvecklings AB and is involved with an EU combidiesel venture and projects of waste heat recovery for heavy duty trucks and passenger cars for leading automotive manufacturers in Europe. He will be Cyclone’s sales representative in Europe. With Peter’s extensive experience in engineering he will focus on licensee development, distribution and integration of Cyclone’s engines and products. Mr. Platell stated: “I am very pleased to join Cyclone’s team. My responsibilities are to obtain licenses for use of Cyclone’s Technology and integration into customers’ systems. In my years of developing steam technology including a very compact water lubricated steam engine I knew when I discovered Cyclone’s Heat Regenerative Engine that they were light years ahead of everyone in the emerging ‘green’ steam power technology field. This is an opportunity for Ranotor steam products to integrate with the Cyclone engine for my customers and future licensee.”

Walter “Eddie” Albright is the President—Marine Power Holdings, LLC. In 1984 Allbright purchased Marine Power- a marine engine manufacturer in New Orleans. At the time the company was doing 150-200 engines a year and selling them to the local commercial shrimping and fishing interests. He has maintained his position as president for the last 30 years. Some of his accomplishments over that period include: Moving the plant from 7000 sf to 30000 sf.; Expansion into the worldwide recreational marketplace.; Increasing production to 3000 units annually; Pioneering gasoline electronic fuel injection into the sport and cruiser boating markets; Designing and procuring engine components for new engine platforms; Obtaining a number of patents related to the marine engine industry; Developing an in-house CNC machine shop; Purchased and improved jet drive tooling to increase market opportunities. In engine testing, Allbright has built a 1065 compliant engine emissions dynometer cell. Certified engine families with the EPA and the California Air Resource Board.

QSAM is CHRIS NELSON
CHRIS NELSON is CYCLONE POWER
CHRIS NELSON is Q2Power

The company did not retain Chris Nelson.. Chris Nelson is the company! He owns the stock shell. He has no interest in building engines, composting, or developing drugs.. This is a penny stock scam designed to enrich Chris Nelson. Nothing else.

Why don't they post their meeting minutes to show the public what is discussed and who shows up??

-Chuck

[Televet]

Good stuff Randy. I spoke with Chris Nelson last week. Seemed up beat.

Said they expect Phase 1 trial to begin in January.

I think he said they have 17 patients.

Trials to last about a year.

Gave some comps. Microbot (MBOT), Quadramet???? and Fusion (FUSN). Pretty healthy market cap (for FSUN- $300M) and in a similar stage of growth as QSAM I believe.

My notes are sketchy, he talks fast..lol.

Anyway some DD on these might give some insight as to what we can expect.

cheers

[RandyKCMO]

WAIT... THERE'S MORE!! R.KEITH FRANK

Over 30 years experience each with Dow Chemical leading R&D efforts in Radiopharmaceuticals & Chelators

Developed Quadramet®

Founded IsoTherapeutics in 2005 performing contract R&D for Big Pharma with emphasis on radiolabeling

Authored/co-authored more than 100 scientific papers & publications
Recognized as leading authorities in radiopharmaceuticals
60+ Patents

Internationally recognized experts in radiopharmaceuticals
Extensive interaction with research institutions, investigators and hospitals

[RandyKCMO]

Any Slouches? nope NOT HERE>>> Barry Sugarman is a Senior Executive Generalist with over 30 years of experience spanning public and private companies in the pharmaceutical, medical device, dietary supplement, and cosmetic industries. Barry has considerable direct experience in pharmaceutical product development, manufacturing, clinical trials, regulatory affairs, FDA and government relations, marketing, and distribution.

Barry possesses broad experience in clinical trial operations and management, mergers, acquisitions, turnarounds, startups, reorganization, process improvements, and sales management and a very strong knowledge of Good Manufacturing Practices (GMP’s), Good Clinical Practices (GCP’s), Good Laboratory Practices (GLP’s), and International Conference for Harmonization (ICH) requirements. He is an author and co-author of numerous FDA filings and approvals including Investigational New Drug Applications (IND’s), New Drug Applications (NDA’s), Abbreviated New Drug Applications (ANDA’s), and Medical Device Applications 510(k)’s.

Barry is a member of the Regulatory Affairs Professional Society (www.raps.org), American Association of Pharmaceutical Scientists (www.aaps.org), Association of Clinical Research Professionals (www.acrpnet.org), and the National Association of Corporate Directors (www.nacdonline.org). He is a co-author of “Prompt, Accurate Diagnosis of Pediatric Cancer and Leukemia for Pediatricians, Orthopedists, and Family Practitioners” – Paperback (Aug. 28, 2007) by Andrew Pendleton, Jennifer Minigh, Lainie Shapiro, and Barry Sugarman.

[RandyKCMO]

Yes, there's more... Dr. Charles J Link is an accomplished physician scientist and experienced executive with decades of biotech and drug development experience. Previously, Dr. Link founded NewLink Genetics, a NASDAQ-listed immunotherapy company focused on developing novel immuno-oncology product candidates. He served as Chairman, CEO and Chief Scientific Officer of NewLink Genetics until his retirement in 2019. During his tenure at NewLink, Dr. Link led a series of collaborative transactions totaling hundreds of millions of dollars with Merck, Roche and the United States government. He also supervised the collaboration between NewLink and Merck to develop EVERBO, the first and only Ebola vaccine to receive FDA and EMA approval.

Dr. Link has been a practicing oncologist for over 30 years and has authored more than 150 peer-reviewed papers. He is inventor on numerous patents in the field of cancer immunotherapy.

[RandyKCMO]

Want some more talent... well here's more: C. Richard Piazza, Ph.D. is a career healthcare executive with 48 years of experience in medical devices as well as the pharmaceutical/biotechnology sectors. Included in this is 44 years in general management positions in both public and private international companies including Ohmeda, Smith & Nephew Pharmaceuticals, Marquest & VitaGen (world’s first bioartifical liver). In 2019 he co-founded QSAM Therapeutics, Inc. with Doug Baum and currently serves as its Executive Chairman.

[RandyKCMO]

For Example: Douglas R. Baum has 28+ years of experience serving in a number of executive management and business development positions within the drug development and life sciences industries. Currently, he serves as the CEO, President and Director of QSAM and its subsidiary, QSAM Therapeutics, Inc., a company he co-founded in 2019. QSAM is an Austin, Texas based clinical stage specialty pharmaceutical company developing a pipeline of radiopharmaceuticals focused on various bone and solid tumor cancers.

[RandyKCMO]

The website details the new officers and board members. Since these men have been successful in the past, I believe there is a great likelihood they will be successful in the future.

https://qsambio.com/#leadership